A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Opicinumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SYNERGY
  • Sponsors Biogen
  • Most Recent Events

    • 28 Oct 2017 Results of a post-hoc analysis studying demographic and baseline predictors of opicinumab treatment response, and identifying a subpopulation with a greater treatment response presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 18 Oct 2017 Data from this trial will be presented at the ECTRIMS-ACTRIMS 2017 meeting, according to a Biogen media release.
    • 28 Apr 2017 Results related to efficacy presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top